LAMY has recently completed a strategic acquisition of Exousia AI, Inc., expanded licensing agreements, and formed partnerships to advance its educational gaming and cancer therapy initiatives.

• LAMY completed the strategic acquisition of cancer therapy innovator Exousia AI, Inc. in December 2025, integrating novel cancer diagnostic and therapy platforms [N3].
• Exousia Pro, Inc. acquired a controlling stake in LAMY in an all-stock exchange transaction to advance growth and enhance shareholder value in November 2025 [N4].
• Exousia Pro, Inc. completed an exclusive licensing agreement with the University of Central Florida for novel cancer diagnostic and therapy platforms in December 2025 [N2].
• Renowned immunologist and urological surgeon Dr. Marvin Hausman was featured in a new Exousia Bio, Inc. interview highlighting scientific expertise in December 2025 [N1].
• LAMY unveiled a GenZ financial literacy initiative powered by user-generated content and creator economy tools in April 2025 [N5].
• LAMY partnered with CREG to launch green energy NFTs and a metaverse-based energy storage demonstration project in April 2025 [N6].
• LAMY formed a strategic partnership with a renowned family to pioneer new integration of NFTs and education in April 2025 [N7].
• LAMY discussed the smart education market entering a golden era of growth in March 2025 [N8].

LAMY's integration of educational gaming with financial literacy and resource management addresses a growing eLearning market. The strategic acquisition of Exousia AI, Inc. adds novel cancer diagnostic and therapeutic platforms, potentially diversifying revenue streams. Partnerships involving NFTs, metaverse projects, and user-generated content position the company to leverage emerging digital trends and creator economy tools, which could enhance engagement and monetization.

LAMY operates as a startup with limited revenue and a net loss position, facing liquidity challenges as indicated by low cash ratios and current assets relative to liabilities. The company competes in highly competitive markets with larger, established players. Execution risks include the ability to commercialize its gaming platform and cancer therapy products, secure additional financing, and protect intellectual property. Regulatory and market acceptance risks also apply, especially in the medical products sector.

LAMY's moat is currently limited as a startup operating in competitive and evolving markets such as educational gaming and cancer therapy. Its strategic acquisition of Exousia AI, Inc. and associated intellectual property, including trademark protection for its twoplus1® brand, provide some proprietary assets. However, the company faces competition from larger, better-capitalized firms and must rely on innovation and niche market penetration to establish competitive advantages.

• Liquidity Risk: As of November 30, 2025, LAMY had a cash ratio of 0.01 and a current ratio of 0, indicating limited liquidity to cover current liabilities, which may constrain operations and growth.
• Competitive Risk: LAMY faces competition from larger, more established companies with greater resources in both the educational gaming and medical products markets.
• Execution Risk: The company is a startup with limited operating history and must successfully commercialize its gaming platform and integrate cancer therapy technologies to generate sustainable revenue.
• Intellectual Property Risk: While LAMY holds trademark protection for its twoplus1® brand, failure to protect or enforce intellectual property rights could diminish product value and competitive positioning.
• Regulatory Risk: The cancer therapy business requires compliance with FDA and other regulations, and any failure to meet these could adversely affect operations.

• LAMY is a startup incorporated in Wyoming in January 2022 focused on the eLearning and gaming markets by teaching financial knowledge and resource management to children through an educational platform, specifically a video game called twoplus1®.
• The twoplus1® game offers an immersive learning experience in finance and real estate with revenue-generating features including virtual property trading generating commissions.
• The company completed a change in control on December 6, 2024, with Zhang Shengwu acquiring approximately 67.51% of outstanding shares and becoming CEO and sole director.
• LAMY completed a strategic acquisition of cancer therapy innovator Exousia AI, Inc. in December 2025, integrating cancer diagnostic and therapy platforms into its business.
• Exousia Pro, Inc. acquired a controlling stake in LAMY in an all-stock exchange transaction to advance growth and enhance shareholder value.
• LAMY has engaged in partnerships and initiatives including a GenZ financial literacy initiative powered by user-generated content and creator economy tools, a green energy NFT and metaverse-based energy storage project with CREG, and strategic partnerships integrating NFTs and education.
• The company holds trademark protection for the twoplus1® brand in the United Kingdom and is pursuing protection in other key regions.
• LAMY's business model emphasizes deploying new technologies and innovations to reduce costs and gain competitive advantages in developing economies, targeting a niche market with relatively low startup costs.
• LAMY's financials as of November 30, 2025, show total assets of approximately $22.05 million, primarily from the acquisition of Exousia AI, Inc., with current liabilities of $261,023 and no reported current assets.
• The company reported no revenue for the six months ended November 30, 2025, and a net loss of $50,897 for the same period.
• Liquidity ratios as of November 30, 2025, indicate a cash and equivalents balance of $1,318 against current liabilities of $261,023, resulting in a cash ratio of 0.01 and a current ratio of 0, indicating liquidity constraints.
• LAMY has not issued stock-based compensation and has no reportable segments as of November 30, 2025.
• The company is not subject to any material legal proceedings and does not require government approval for its principal products or services.
• LAMY's recent developments include strategic acquisitions, licensing agreements, and partnerships aimed at expanding its product offerings in cancer therapy and educational gaming markets.